{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T23:58:10Z","timestamp":1779926290941,"version":"3.53.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,4,16]],"date-time":"2020-04-16T00:00:00Z","timestamp":1586995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,4,16]],"date-time":"2020-04-16T00:00:00Z","timestamp":1586995200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Drug resistance in <jats:italic>Clostridioides difficile<\/jats:italic> becomes a public health concern worldwide, especially as the hypervirulent strains show decreased susceptibility to the first-line antibiotics for <jats:italic>C. difficile<\/jats:italic> treatment. Therefore, the simultaneous discovery and development of new compounds to fight this pathogen are urgently needed. In order to determinate new drugs active against <jats:italic>C. difficile<\/jats:italic>, we identified ticagrelor, utilized for the prevention of thrombotic events, as exhibiting potent growth-inhibitory activity against <jats:italic>C. difficile<\/jats:italic>. Whole-cell growth inhibition assays were performed and compared to vancomycin and metronidazole, followed by determining time-kill kinetics against <jats:italic>C. difficile<\/jats:italic>. Activities against biofilm formation and spore germination were also evaluated. Leakage analyses and electron microscopy were applied to confirm the disruption of membrane structure. Finally, ticagrelor\u2019s ability to synergize with vancomycin and metronidazole was determined using checkerboard assays. Our data showed that ticagrelor exerted activity with a MIC range of 20\u201340\u2009\u00b5g\/mL against <jats:italic>C. difficile<\/jats:italic>. This compound also exhibited an inhibitory effect on biofilm formation and spore germination. Additionally, ticagrelor did not interact with vancomycin nor metronidazole. Our findings revealed for the first time that ticagrelor could be further developed as a new antimicrobial agent for fighting\u00a0against <jats:italic>C. difficile<\/jats:italic>.<\/jats:p>","DOI":"10.1038\/s41598-020-63199-x","type":"journal-article","created":{"date-parts":[[2020,4,16]],"date-time":"2020-04-16T10:03:11Z","timestamp":1587031391000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Repurposing a platelet aggregation inhibitor ticagrelor as an antimicrobial against Clostridioides difficile"],"prefix":"10.1038","volume":"10","author":[{"given":"Matthew","family":"Phanchana","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanaporn","family":"Phetruen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phurt","family":"Harnvoravongchai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ponlawoot","family":"Raksat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Puey","family":"Ounjai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Surang","family":"Chankhamhaengdecha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tavan","family":"Janvilisri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,4,16]]},"reference":[{"key":"63199_CR1","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.anaerobe.2016.06.008","volume":"40","author":"PA Lawson","year":"2016","unstructured":"Lawson, P. A., Citron, D. M., Tyrrell, K. L. & Finegold, S. M. Reclassification of Clostridium difficile as Clostridioides difficile (Hall and O\u2019Toole 1935) Prevot 1938. Anaerobe 40, 95\u201399, https:\/\/doi.org\/10.1016\/j.anaerobe.2016.06.008 (2016).","journal-title":"Anaerobe"},{"key":"63199_CR2","unstructured":"CDC. Antibiotic Resistance Threats in the United States, 2019. (Atlanta, GA, 2019)."},{"key":"63199_CR3","doi-asserted-by":"publisher","first-page":"3881","DOI":"10.1128\/jb.00222-09","volume":"191","author":"T Janvilisri","year":"2009","unstructured":"Janvilisri, T. et al. Microarray identification of Clostridium difficile core components and divergent regions associated with host origin. J. Bacteriol. 191, 3881\u20133891, https:\/\/doi.org\/10.1128\/jb.00222-09 (2009).","journal-title":"J. Bacteriol."},{"key":"63199_CR4","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1007\/s10096-019-03539-6","volume":"38","author":"J Czepiel","year":"2019","unstructured":"Czepiel, J. et al. Clostridium difficile infection: review. Eur. J. Clin. Microbiol. Infect. Dis. 38, 1211\u20131221, https:\/\/doi.org\/10.1007\/s10096-019-03539-6 (2019).","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"63199_CR5","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1093\/cid\/cix1085","volume":"66","author":"LC McDonald","year":"2018","unstructured":"McDonald, L. C. et al. Clinical practice guidelines for Clostridium difficile infection in adults and children: 2017 update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin. Infect. Dis. 66, e1\u2013e48, https:\/\/doi.org\/10.1093\/cid\/cix1085 (2018).","journal-title":"Clin. Infect. Dis."},{"key":"63199_CR6","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1042\/ebc20160062","volume":"61","author":"P Harnvoravongchai","year":"2017","unstructured":"Harnvoravongchai, P., Pipatthana, M., Chankhamhaengdecha, S. & Janvilisri, T. Insights into drug resistance mechanisms in Clostridium difficile. Essays Biochem. 61, 81\u201388, https:\/\/doi.org\/10.1042\/ebc20160062 (2017).","journal-title":"Essays Biochem."},{"key":"63199_CR7","doi-asserted-by":"publisher","first-page":"2892","DOI":"10.1093\/jac\/dku261","volume":"69","author":"OA Cornely","year":"2014","unstructured":"Cornely, O. A. et al. Clinical efficacy of fidaxomicin compared with vancomycin and metronidazole in Clostridium difficile infections: a meta-analysis and indirect treatment comparison. J. Antimicrob. Chemother. 69, 2892\u20132900, https:\/\/doi.org\/10.1093\/jac\/dku261 (2014).","journal-title":"J. Antimicrob. Chemother."},{"key":"63199_CR8","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1111\/nyas.13958","volume":"1435","author":"MG Dieterle","year":"2019","unstructured":"Dieterle, M. G., Rao, K. & Young, V. B. Novel therapies and preventative strategies for primary and recurrent Clostridium difficile infections. Ann. N Y. Acad. Sci. 1435, 110\u2013138, https:\/\/doi.org\/10.1111\/nyas.13958 (2019).","journal-title":"Ann. N Y. Acad. Sci."},{"key":"63199_CR9","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/nrd1468","volume":"3","author":"TT Ashburn","year":"2004","unstructured":"Ashburn, T. T. & Thor, K. B. Drug repositioning: identifying and developing new uses for existing drugs. Nat. Rev. Drug Discov. 3, 673\u2013683, https:\/\/doi.org\/10.1038\/nrd1468 (2004).","journal-title":"Nat. Rev. Drug Discov."},{"key":"63199_CR10","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1001\/jamacardio.2019.1189","volume":"4","author":"P Lancellotti","year":"2019","unstructured":"Lancellotti, P. et al. Antibacterial activity of ticagrelor in conventional antiplatelet dosages against antibiotic-resistant Gram-positive bacteria. JAMA Cardiol 4, 596\u2013599, https:\/\/doi.org\/10.1001\/jamacardio.2019.1189 (2019).","journal-title":"JAMA Cardiol"},{"key":"63199_CR11","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1128\/AAC.00999-09","volume":"54","author":"J Meletiadis","year":"2010","unstructured":"Meletiadis, J., Pournaras, S., Roilides, E. & Walsh, T. J. Defining fractional inhibitory concentration index cutoffs for additive interactions based on self-drug additive combinations, Monte Carlo simulation analysis, and in vitro-in vivo correlation data for antifungal drug combinations against Aspergillus fumigatus. Antimicrob. Agents Chemother. 54, 602\u2013609, https:\/\/doi.org\/10.1128\/AAC.00999-09 (2010).","journal-title":"Antimicrob. Agents Chemother."},{"key":"63199_CR12","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.4161\/hv.28428","volume":"10","author":"R Leuzzi","year":"2014","unstructured":"Leuzzi, R., Adamo, R. & Scarselli, M. Vaccines against Clostridium difficile. Hum. Vaccin. Immunother. 10, 1466\u20131477, https:\/\/doi.org\/10.4161\/hv.28428 (2014).","journal-title":"Hum. Vaccin. Immunother."},{"key":"63199_CR13","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1099\/jmm.0.038174-0","volume":"61","author":"LA Vitali","year":"2012","unstructured":"Vitali, L. A. et al. In vitro antibacterial activity of different adenosine analogues. J. Med. Microbiol. 61, 525\u2013528, https:\/\/doi.org\/10.1099\/jmm.0.038174-0 (2012).","journal-title":"J. Med. Microbiol."},{"key":"63199_CR14","doi-asserted-by":"publisher","first-page":"10343","DOI":"10.1021\/acs.jmedchem.6b00325","volume":"59","author":"M Serpi","year":"2016","unstructured":"Serpi, M., Ferrari, V. & Pertusati, F. Nucleoside derived antibiotics to fight microbial drug resistance: new utilities for an established class of drugs? J. Med. Chem. 59, 10343\u201310382, https:\/\/doi.org\/10.1021\/acs.jmedchem.6b00325 (2016).","journal-title":"J. Med. Chem."},{"key":"63199_CR15","doi-asserted-by":"publisher","first-page":"3008","DOI":"10.1128\/AAC.04830-14","volume":"59","author":"X Zhu","year":"2015","unstructured":"Zhu, X. et al. Bactericidal efficiency and modes of action of the novel antimicrobial peptide T9W against Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 59, 3008\u20133017, https:\/\/doi.org\/10.1128\/AAC.04830-14 (2015).","journal-title":"Antimicrob. Agents Chemother."},{"key":"63199_CR16","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1128\/AAC.01053-10","volume":"55","author":"EC Spindler","year":"2011","unstructured":"Spindler, E. C., Hale, J. D., Giddings, T. H. Jr., Hancock, R. E. & Gill, R. T. Deciphering the mode of action of the synthetic antimicrobial peptide Bac8c. Antimicrob. Agents Chemother. 55, 1706\u20131716, https:\/\/doi.org\/10.1128\/AAC.01053-10 (2011).","journal-title":"Antimicrob. Agents Chemother."},{"key":"63199_CR17","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.3389\/fmicb.2018.01593","volume":"9","author":"BC Chen","year":"2018","unstructured":"Chen, B. C. et al. Phenanthrene antibiotic targets bacterial membranes and kills Staphylococcus aureus with a low propensity for resistance development. Front. Microbiol. 9, 1593, https:\/\/doi.org\/10.3389\/fmicb.2018.01593 (2018).","journal-title":"Front. Microbiol."},{"key":"63199_CR18","doi-asserted-by":"publisher","first-page":"794","DOI":"10.3389\/fmicb.2018.00794","volume":"9","author":"JM Radziwill-Bienkowska","year":"2018","unstructured":"Radziwill-Bienkowska, J. M. et al. Toxicity of food-grade TiO2 to commensal intestinal and transient food-borne bacteria: new insights using Nano-SIMS and synchrotron UV fluorescence imaging. Front. Microbiol. 9, 794, https:\/\/doi.org\/10.3389\/fmicb.2018.00794 (2018).","journal-title":"Front. Microbiol."},{"key":"63199_CR19","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1038\/nrmicro.2016.108","volume":"14","author":"MC Abt","year":"2016","unstructured":"Abt, M. C., McKenney, P. T. & Pamer, E. G. Clostridium difficile colitis: pathogenesis and host defence. Nat. Rev. Microbiol. 14, 609\u2013620, https:\/\/doi.org\/10.1038\/nrmicro.2016.108 (2016).","journal-title":"Nat. Rev. Microbiol."},{"key":"63199_CR20","doi-asserted-by":"publisher","first-page":"397","DOI":"10.4161\/gmic.25862","volume":"4","author":"T Dapa","year":"2013","unstructured":"Dapa, T. & Unnikrishnan, M. Biofilm formation by Clostridium difficile. Gut Microbes 4, 397\u2013402, https:\/\/doi.org\/10.4161\/gmic.25862 (2013).","journal-title":"Gut Microbes"},{"key":"63199_CR21","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/978-3-319-72799-8_7","volume":"1050","author":"C Vuotto","year":"2018","unstructured":"Vuotto, C., Donelli, G., Buckley, A. & Chilton, C. Clostridium difficile biofilm. Adv. Exp. Med. Biol. 1050, 97\u2013115, https:\/\/doi.org\/10.1007\/978-3-319-72799-8_7 (2018).","journal-title":"Adv. Exp. Med. Biol."},{"key":"63199_CR22","doi-asserted-by":"publisher","unstructured":"Vuotto, C., Moura, I., Barbanti, F., Donelli, G. & Spigaglia, P. Subinhibitory concentrations of metronidazole increase biofilm formation in Clostridium difficile strains. Pathog Dis 74, https:\/\/doi.org\/10.1093\/femspd\/ftv114 (2016).","DOI":"10.1093\/femspd\/ftv114"},{"key":"63199_CR23","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.tim.2014.04.003","volume":"22","author":"D Paredes-Sabja","year":"2014","unstructured":"Paredes-Sabja, D., Shen, A. & Sorg, J. A. Clostridium difficile spore biology: sporulation, germination, and spore structural proteins. Trends Microbiol. 22, 406\u2013416, https:\/\/doi.org\/10.1016\/j.tim.2014.04.003 (2014).","journal-title":"Trends Microbiol."},{"key":"63199_CR24","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-14-29","volume":"14","author":"JR Garneau","year":"2014","unstructured":"Garneau, J. R., Valiquette, L. & Fortier, L. C. Prevention of Clostridium difficile spore formation by sub-inhibitory concentrations of tigecycline and piperacillin\/tazobactam. BMC Infect. Dis. 14, 29, https:\/\/doi.org\/10.1186\/1471-2334-14-29 (2014).","journal-title":"BMC Infect. Dis."},{"key":"63199_CR25","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1093\/jac\/dks359","volume":"68","author":"GS Crowther","year":"2013","unstructured":"Crowther, G. S. et al. Evaluation of NVB302 versus vancomycin activity in an in vitro human gut model of Clostridium difficile infection. J. Antimicrob. Chemother. 68, 168\u2013176, https:\/\/doi.org\/10.1093\/jac\/dks359 (2013).","journal-title":"J. Antimicrob. Chemother."},{"key":"63199_CR26","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1021\/acsomega.7b01740","volume":"3","author":"K Mitachi","year":"2018","unstructured":"Mitachi, K. et al. Novel FR-900493 Analogues that inhibit the outgrowth of Clostridium difficile spores. ACS Omega 3, 1726\u20131739, https:\/\/doi.org\/10.1021\/acsomega.7b01740 (2018).","journal-title":"ACS Omega"},{"key":"63199_CR27","doi-asserted-by":"publisher","first-page":"29","DOI":"10.3389\/fcimb.2018.00029","volume":"8","author":"D Zhu","year":"2018","unstructured":"Zhu, D., Sorg, J. A. & Sun, X. Clostridioides difficile biology: sporulation, germination, and corresponding therapies for C. difficile infection. Front Cell Infect Microbiol 8, 29, https:\/\/doi.org\/10.3389\/fcimb.2018.00029 (2018).","journal-title":"Front Cell Infect Microbiol"},{"key":"63199_CR28","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1002\/phar.1477","volume":"34","author":"PP Dobesh","year":"2014","unstructured":"Dobesh, P. P. & Oestreich, J. H. Ticagrelor: pharmacokinetics, pharmacodynamics, clinical efficacy, and safety. Pharmacotherapy 34, 1077\u20131090, https:\/\/doi.org\/10.1002\/phar.1477 (2014).","journal-title":"Pharmacotherapy"},{"key":"63199_CR29","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.1124\/dmd.110.032250","volume":"38","author":"R Teng","year":"2010","unstructured":"Teng, R., Oliver, S., Hayes, M. A. & Butler, K. Absorption, distribution, metabolism, and excretion of ticagrelor in healthy subjects. Drug Metab. Dispos. 38, 1514\u20131521, https:\/\/doi.org\/10.1124\/dmd.110.032250 (2010).","journal-title":"Drug Metab. Dispos."},{"key":"63199_CR30","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1208\/s12249-015-0350-9","volume":"16","author":"S Amidon","year":"2015","unstructured":"Amidon, S., Brown, J. E. & Dave, V. S. Colon-targeted oral drug delivery systems: design trends and approaches. AAPS PharmSciTech 16, 731\u2013741, https:\/\/doi.org\/10.1208\/s12249-015-0350-9 (2015).","journal-title":"AAPS PharmSciTech"},{"key":"63199_CR31","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1055\/s-2005-869525","volume":"31","author":"JJ van Giezen","year":"2005","unstructured":"van Giezen, J. J. & Humphries, R. G. Preclinical and clinical studies with selective reversible direct P2Y12 antagonists. Semin. Thromb. Hemost. 31, 195\u2013204, https:\/\/doi.org\/10.1055\/s-2005-869525 (2005).","journal-title":"Semin. Thromb. Hemost."},{"key":"63199_CR32","unstructured":"Clinical and Laboratory Standards Institute. Methods for Antimicrobial Susceptibility Testing of Anaerobic Bacteria, 6th Edition. CLSI document M11-A6. Clinical and Laboratory Standards Institute (Wayne, PA, 2004)."},{"key":"63199_CR33","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.3389\/fmicb.2018.02125","volume":"9","author":"P Harnvoravongchai","year":"2018","unstructured":"Harnvoravongchai, P. et al. Antimicrobial effect of asiatic acid against Clostridium difficile is associated with disruption of membrane permeability. Front. Microbiol. 9, 2125, https:\/\/doi.org\/10.3389\/fmicb.2018.02125 (2018).","journal-title":"Front. Microbiol."},{"key":"63199_CR34","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1186\/1472-6882-14-329","volume":"14","author":"EN Hammond","year":"2014","unstructured":"Hammond, E. N., Donkor, E. S. & Brown, C. A. Biofilm formation of Clostridium difficile and susceptibility to Manuka honey. BMC Complement. Altern. Med. 14, 329, https:\/\/doi.org\/10.1186\/1472-6882-14-329 (2014).","journal-title":"BMC Complement. Altern. Med."},{"key":"63199_CR35","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01225-19","author":"M Alhashimi","year":"2019","unstructured":"Alhashimi, M., Mayhoub, A. & Seleem, M. N. Repurposing salicylamide for combating multidrug-resistant Neisseria gonorrhoeae. Antimicrob. Agents Chemother. https:\/\/doi.org\/10.1128\/AAC.01225-19 (2019).","journal-title":"Antimicrob. Agents Chemother."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-63199-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-63199-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-63199-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T09:43:29Z","timestamp":1670319809000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-63199-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,16]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["63199"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-63199-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,16]]},"assertion":[{"value":"6 January 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"6497"}}